http://biz.yahoo.com/prnews/061127/mo397.html?.v=2
November 27, 2006 (PRNewswire)- Six-week Follow-up Results of Phase I/IIa Trial Show Safety, Tolerability and Neurological Outcome of Cethrin(R): BioAxone Therapeutic announced today positive interim results on its Phase I/IIa North American dose escalation clinical trial on Cethrin® for the treatment of acute spinal cord injury (SCI). The Company reported that data on safety, tolerability and neurological outcome from the six-week follow-up of the trial of Cethrin® at four dose levels (0.3, 1, 3 and 6 mg) indicates that this treatment is safe and well tolerated and that the functional benefit may be dose dependent…